Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Development of viral vectors capable of transducing photoreceptors by less invasive methods than subretinal injection would provide a major advancement in retinal gene therapy. We sought to develop novel AAV vectors optimized for photoreceptor transduction following intravitreal delivery and to develop methodology for quantifying this transduction in vivo. Surface exposed tyrosine (Y) and threonine (T) residues on the capsids of AAV2, AAV5 and AAV8 were changed to phenylalanine (F) and valine (V), respectively. Transduction efficiencies of self-complimentary, capsid-mutant and unmodified AAV vectors containing the smCBA promoter and mCherry cDNA were initially scored in vitro using a cone photoreceptor cell line. Capsid mutants exhibiting the highest transduction efficiencies relative to unmodified vectors were then injected intravitreally into transgenic mice constitutively expressing a Rhodopsin-GFP fusion protein in rod photoreceptors (Rho-GFP mice). Photoreceptor transduction was quantified by fluorescent activated cell sorting (FACS) by counting cells positive for both GFP and mCherry. To explore the utility of the capsid mutants, standard, (non-self-complementary) AAV vectors containing the human rhodopsin kinase promoter (hGRK1) were made. Vectors were intravitreally injected in wildtype mice to assess whether efficient expression exclusive to photoreceptors was achievable. To restrict off-target expression in cells of the inner and middle retina, subsequent vectors incorporated multiple target sequences for miR181, an miRNA endogenously expressed in the inner and middle retina. Results showed that AAV2 containing four Y to F mutations combined with a single T to V mutation (quadY-F+T-V) transduced photoreceptors most efficiently. Robust photoreceptor expression was mediated by AAV2(quadY-F+T-V) -hGRK1-GFP. Observed off-target expression was reduced by incorporating target sequence for a miRNA highly expressed in inner/middle retina, miR181c. Thus we have identified a novel AAV vector capable of transducing photoreceptors following intravitreal delivery to mouse. Furthermore, we describe a robust methodology for quantifying photoreceptor transduction from intravitreally delivered AAV vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since surface-exposed residues on AAV capsids can be ubiquitinated through phosphorylation, mutations of these residues (e.g. tyrosine, lysine, serine) to reduce the likelihood of ubiquitination can generate novel capsids with reduced ubiquitination, antigen presentation, and activated cellular immunity (92 -99).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [95]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Clinical trials for RPE65-Leber congenital amaurosis (LCA) have demonstrated the ability to deliver therapeutic transgene to the retinal pigment epithelium (RPE) by subretinal injection thereby restoring retinal function and visually-evoked behavior to patients [1–3].”
BackgroundSelf-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Clinical trials for RPE65-Leber congenital amaurosis (LCA) have demonstrated the ability to deliver therapeutic transgene to the retinal pigment epithelium (RPE) by subretinal injection thereby restoring retinal function and visually-evoked behavior to patients [1–3].”
BackgroundSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 7×
“In primate, the ILM is significantly thicker, except for an area in and around the fovea and immediately above large blood vessels [56].”
BackgroundInfluentialGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
MethodSelf-citation(1984) · PubMed · Cited by 1,200
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“Adeno-associated virus (AAV) is considered the optimal vector for ocular gene therapy due to its efficiency, persistence and low immunogenicity [7].”
BackgroundRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741 · cited 1×
“Promoter constructs were identical to those previously described [31,33,34].”
ResultJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639 · cited 1×
“reported that subretinal injection under a cone-rich fovea resulted in decreased visual acuity (in some LCA2 patients) and foveal thinning (in both LCA2 patients and non-human primates) [5,6].”
BackgroundPhotoreceptor degeneration: genetic and mechanistic dissection of a complex trait
Wright, A. F., Chakarova, C. F., Abd El-Aziz, M. M., & Bhattacharya, S. S. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2717 · Cited by 631 · cited 1×
“Given the predominance of photoreceptor (PR) specific retinal degenerations [4], there is a need to develop PR targeted gene therapies.”
Background
Cited by
Items 101–168 of 168
Ross, M., Obolensky, A., Averbukh, E., Ezra-Elia, R., Yamin, E., Honig, H., Dvir, H., Rosov, A., Hauswirth, W. W., Gootwine, E., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.023 · Cited by 16
“17 Previous proof of concept studies have shown successful photoreceptor transduction by these modified vectors following intravitreal injection in murine and canine eyes, 17,18,23,24 and this compelled us to repeat the trials in our large animal model of CNGA3 achromatopsia.”
InfluentialSelf-citationRetinal gene therapy: current progress and future prospects
Ku, C. A., & Pennesi, M. E. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1035711 · Cited by 18
“While Y-F capsid mutants provided initial proof-of-concept for intravitreal transduction of outer retinal cells in mice [47,66], transduction was highly limited or absent in canine [67] and non-human primates (NHPs) [65].”
BackgroundProceedings of the First International Optogenetic Therapies for Vision Symposium
Francis, P. J., Mansfield, B. C., & Rose, S. (2013) · Translational Vision Science & Technology · doi:10.1167/tvst.2.7.4 · Cited by 18
“William Hauswirth highlighted ongoing research efforts to selectively mutate AAV to gain better retinal penetration and transduction efficiency by altering viral surface tyrosine moieties.(60) With this work currently making good progress, he identified that the current major hindrance to retinal cell targeting as the…”
BackgroundStacking up CRISPR against RNA i for therapeutic gene inhibition
Haussecker, D. (2016) · FEBS Journal · doi:10.1111/febs.13742 · Cited by 18
Gene Therapy for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa
Massengill, M. T., & Lewin, A. S. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000383 · Cited by 20
Markus, A., Shamul, A., Chemla, Y., Farah, N., Shaham, L., Goldstein, R. S., & Mandel, Y. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.11.013 · Cited by 14
Ezra-Elia, R., Obolensky, A., Ejzenberg, A., Ross, M., Mintz, D., Banin, E., & Ofri, R. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.08.021 · Cited by 14
What Is Next for Retinal Gene Therapy?
Vandenberghe, L. H. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017442 · Cited by 12
“Last, efficient and safe targeting from the vitreous would overcome several shortcomings of the subretinal injection route and, certainly, make gene therapy a more routine clinical procedure (Dalkara et al. 2013; Kay et al. 2013).”
BackgroundAAVrh-10 transduces outer retinal cells in rodents and rabbits following intravitreal administration
Zeng, Y., Qian, H., Wu, Z., Marangoni, D., Sieving, P. A., & Bush, R. A. (2019) · Gene Therapy · doi:10.1038/s41434-019-0094-3 · Cited by 12
Tian, X., Zheng, Q., Xie, J., Zhou, Q., Liang, L., Xu, G., Chen, H., Ling, C., & Lu, D. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.001 · Cited by 14
Systemic Delivery of Genes to Retina Using Adeno-Associated Viruses
Simpson, C. P., Bolch, S. N., Zhu, P., Weidert, F., Dinculescu, A., & Lobanova, E. S. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-27378-1_18 · Cited by 11
A review of the 661W cell line as a tool to facilitate treatment development for retinal diseases
Brunet, A. A., James, R. E., Swanson, P., & Carvalho, L. S. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01381-2 · Cited by 13
“AAV5 and AAV8 shown to outperform AAV2 at transducing photoreceptors in vivo despite the popular use of AAV2 [139, 145–148].”
Gene Therapy Rescues Retinal Degeneration in Receptor Expression-Enhancing Protein 6 Mutant Mice
Zaneveld, S. A., Eblimit, A., Liang, Q., Bertrand, R. E., Wu, N., Liu, H., Nguyen, Q., Zaneveld, J. E., Wang, K., Li, Y., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.078 · Cited by 12
“1 construct is under the control of the human rhodopsin kinase (hGRK1) promotor, which has been established to be the most effective combination for attaining rapid and high transgene expression in mouse photoreceptors.(45) Furthermore, to distinguish the vectored wild-type REEP6.”
BackgroundCasey, G. A., Papp, K. M., & MacDonald, I. M. (2020) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v15i3.7457 · Cited by 15
“[3] Wild-type AAV vector capsids do not penetrate deeply into the retina when administered intravitreally, but the ability of novel AAV capsids (produced via directed evolution) to transduce the posterior cells of the retina is under investigation.[4, 5] An additional barrier to successful transduction of any retinal…”
BackgroundDeveloping New Vectors for Retinal Gene Therapy
Zin, E. A., Öztürk, B. E., Dalkara, D., & Byrne, L. C. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041291 · Cited by 14
Cellular and subcellular optogenetic approaches towards neuroprotection and vision restoration
Wood, E. H., Kreymerman, A., Kowal, T. J., Buickians, D. N., Sun, Y., Muscat, S. P., Mercola, M. A., Moshfeghi, D. M., & Goldberg, J. L. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101153 · Cited by 13
Expression of a CARD Slows the Retinal Degeneration of a Geographic Atrophy Mouse Model
Young, B. M., Jones, K., Massengill, M. T., Walsh, E., Li, H., Lewin, A. S., & Ildefonso, C. J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.001 · Cited by 12
“This AAV2quad(Y-F) + T491V mutant capsid allows the efficient transduction of retinal ganglion cells and bipolar cells, but not photoreceptor cells or the RPE, after an intravitreal injection in mice.(17) This AAV2quad(Y-F) + T491V delivering a secretable GFP (sGFP) fused to a trans-activator of transcription (Tat)CAR…”
BackgroundAAV Mediated Delivery of Myxoma Virus M013 Gene Protects the Retina against Autoimmune Uveitis
Ridley, R. B., Young, B. M., Lee, J., Walsh, E. M., Ahmed, C. M. I., Lewin, A. S., & Ildefonso, C. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122082 · Cited by 10
“who demonstrated its ability to transduce multiple retina cells after an intravitreal injection [26].”
BackgroundMethodLa conception de vecteurs adaptés à la thérapie génique oculaire
Khabou, H., & Dalkara, D. (2015) · médecine/sciences · doi:10.1051/medsci/20153105015 · Cited by 17
“31, mai 2015 d’améliorer cette efficacité [30].”
Tan, J., Zhang, X., Li, D., Liu, G., Wang, Y., Zhang, D., Wang, X., Tian, W., Dong, X., Zhou, L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.014 · Cited by 11
“In addition, the scAAV2 vector transduces RGCs around the optic nerve head more efficiently than do scAAV5 and scAAV8 after intravitreal injection.(43,44) Intravitreally delivered ssAAV2 had a marginally higher efficiency of transduction of both outer and inner retinas than did scAAV2, while scAAV2 showed a more rapid…”
BackgroundX-linked Retinoschisis and Gene Therapy
Mishra, A., & Sieving, P. A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000373 · Cited by 10
Stem cell transplantation as a progressing treatment for retinitis pigmentosa
Shabanan, S. H., Seyedmirzaei, H., Barnea-Cramer, A. O., Hanaei, S., & Rezaei, N. (2022) · Cell and Tissue Research · doi:10.1007/s00441-021-03551-3 · Cited by 11
Gene Therapy to Rescue Retinal Degeneration Caused by Mutations in Rhodopsin
Rossmiller, B. P., Ryals, R. C., & Lewin, A. S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2330-4_25 · Cited by 11
“However, capsid modifications of AAV have permitted transduction of up to 25 % of photoreceptors in mice following intravitreal injections [20].”
BackgroundSelf-citationMassengill, M. T., Young, B. M., Lewin, A. S., & Ildefonso, C. J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9065-8_15 · Cited by 9
Lipinski, D. M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-27378-1_13 · Cited by 8
IRAM: virus capsid database and analysis resource
Almansour, I., Alhagri, M., Alfares, R., Alshehri, M. A., Bakhashwain, R., & Maarouf, A. A. (2019) · Database · doi:10.1093/database/baz079 · Cited by 8
Novel Methodology for Creating Macaque Retinas with Sortable Photoreceptors and Ganglion Cells
Choudhury, S., Strang, C. E., Alexander, J. J., Scalabrino, M. L., Hill, J. L., Kasuga, D. T., Witherspoon, C. D., Boye, S. L., Gamlin, P. D., & Boye, S. L. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00551 · Cited by 9
“As has been previously done with transgenic reporter mouse models (Kay et al., 2013; Cronin et al., 2014; Boye et al., 2016), this approach can also be used as a screening method for identifying novel viral vectors (i.”
MethodSelf-citationEffect of Proteasome Inhibitors on the AAV-Mediated Transduction Efficiency in Retinal Bipolar Cells
Cui, S., Ganjawala, T. H., Abrams, G. W., & Pan, Z. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200211111326 · Cited by 7
Cwerman‐Thibault, H., Lechauve, C., Malko-Baverel, V., Augustin, S., Guilloux, G. L., Reboussin, É., Dégardin, J., Simonutti, M., Debeir, T., & Corral‐Debrinski, M. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105483 · Cited by 8
Nakahama, R., Saito, A., Nobe, S., Togashi, K., Suzuki, I., Uematsu, A., & Emoto, K. (2022) · Molecular Brain · doi:10.1186/s13041-022-00957-0 · Cited by 7
Optogenetics and prosthetic treatment of retinal degeneration
Kirpichnikov, M. P., & Ostrovskiy, M. A. (2015) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2015131399-111 · Cited by 7
“Недавно предпринята попытка получения мутанта аденоассоциированного вируса, способного более эффективно доставлять ген (гены) к клеточным элементам сетчатки [47].”
Kwon, H.-J., Qing, K., Ponnazhagan, S., Wang, X.-S., Markusic, D. M., Gupte, S., Boye, S. E., & Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.018 · Cited by 6
“Ocular injections Intravitreal AAV vector injections were administered as previously described.(33) C57BL6/J mice were intravitreally injected in their right eyes (REs) with 3 · 10(11) vg/ mL of scAAV2-EGFP (n = 8) or with scAAV2-X-boxEGFP (n = 8) vectors (1 lL delivered).”
MethodSelf-citationZhang, H., Sajdak, B. S., Merriman, D. K., Carroll, J., & Lipinski, D. M. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.005 · Cited by 6
Restoration of synaptic function in sight for degenerative retinal disease
Schubert, T., & Wissinger, B. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82577 · Cited by 6
Brown, B. L., Zalla, R. M., Shepard, C. T., Howard, R. M., Kopechek, J. A., Magnuson, D. S. K., & Whittemore, S. R. (2021) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2021.635921 · Cited by 6
“Previous studies have shown that changes to the AAV capsid impact the rate of viral degradation and subsequent transgene expression (Zhong et al., 2008a,b; Kay et al., 2013).”
ResultGene therapy shines light on congenital stationary night blindness for future cures
Zhang, Y., Lin, S., Yu, L., Lin, X. Y., Qu, S., Ye, Q., Yu, M., Chen, W., & Wu, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06392-8 · Cited by 5
“Miranda and his team previously developed an AAV vector named AAV2(quadY-F + TV), which was engineered to enhance transduction efficiency in photoreceptor cells (PR) by targeted mutagenesis of tyrosine and threonine residues on the AAV2 capsid [189].”
Viral Vector Technologies and Strategies: Improving on Nature
Croze, R. H., Kotterman, M. A., Burns, C. H., Schmitt, C. E., Quezada, M., Schaffer, D. V., Kirn, D. H., & Francis, P. J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000361 · Cited by 5
Gene Therapy for Inherited Retinopathies: Update on Development Progress
Sun, S. Y., & Montezuma, S. R. (2018) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126418783934 · Cited by 6
Gene Therapy for Rhodopsin Mutations
Lewin, A. S., & Smith, W. C. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041283 · Cited by 7
Gene Therapy for Retinal Diseases
Gopinath, C., Sarkar, S., & Ghosh, A. (2021) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-15-9184-6_30 · Cited by 3
Chern, K. J., Isaac, K., Gumbs, Z. D., O’Connor, M. E., Lawrence, M. S., & Lipinski, D. M. (2023) · Gene Therapy · doi:10.1038/s41434-023-00407-z · Cited by 2
“Traditionally, ocular gene therapy has primarily been focused on two major injection routes—intravitreal and subretinal—in order to target differing layers of the retina or retinal pigment epithelium (RPE) for the treatment of inherited retinal diseases, with relatively little research focused on the use of rAAV vecto…”
BackgroundGene Therapy in Age-related Macular Degeneration
Zhou, H. W., & Kim, L. A. (2025) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000567 · Cited by 4
Virus Vectors for Optogenetic Prosthetization of the Retina
Rotov, A. Y., Nikolaeva, D. A., Astakhova, L. A., & Firsov, M. L. (2020) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-020-00911-4 · Cited by 2
Chapter 3 - Restoring Vision to the Blind: Gene Therapy for Vision Loss
Science, T. L. I. I. F. I. I. V. S. T. L. I. I. F. I. I. V. (2014) · Translational Vision Science & Technology · doi:10.1167/tvst.3.7.5 · Cited by 4
Improved intravitreal injection procedure in mice with electroretinographic evaluation of results
Romanov, I. S., Rotov, A. Y., Astakhova, L. A., & Firsov, M. L. (2022) · Integrative Physiology · doi:10.33910/2687-1270-2022-3-2-233-245 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Gene Therapy in the Treatment of Geographic Atrophy
Csaky, K. G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000387 · Cited by 1
Gene Therapy, Diet and Drug Approaches to Treating Inherited Retinal Disease
Simunovic, M. P., Mack, H. G., Ayton, L. N., & Hassall, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00154-7 · Cited by 3
Ebner, L. J. A., Imsand, C., Karademir, D., Peters, F., Kiessling, E., Fottner, A., Matter, C., Fajardo, D. S., Merolla, L., Wögenstein, G. M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.044 · Cited by 2
Self-citationBorghuis, B. G. (2019) · Neuromethods · doi:10.1007/978-1-4939-9702-2_5 · Cited by 1
Hassall, M., & Simunovic, M. P. (2020) · Springer eBooks · doi:10.1007/978-981-15-7644-7_35 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
Wögenstein, G. M., Ravotto, L., Todorova, V., Meister, R., Samardzija, M., Weber, B., & Grimm, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.02.709047 · Cited by 1
Improving Aav Transduction Efficiency In Retinal Bipolar Cells For Optogenetic Vision Restoration
Cui, S. (2018) · Human Biology
Staff, T. P. O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110030
de Guimarães, T. A. C., & Michaelides, M. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_16
Cao, B., Mühlfriedel, R. L., Sen, M., Almansa-Garcia, A.-C., Seeliger, M. W., Petremann-Dumé, A.-S., Kilger, E., Vollert, A., Bolz, S., Henes, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.25.661245
Nakahama, R., Saito, A., Nobe, S., Togashi, K., Suzuki, I., Uematsu, A., & Emoto, K. (2022) · Figshare · doi:10.6084/m9.figshare.20454607
Neuillé, M. (2016) · theses.fr (ABES) · doi:10.70675/d55545d7ze4aaz43cfzbed2za2c6147a1901 · Cited by 1
Evolution dirigée de virus adéno-associés pour un transfert de gène efficace dans le système visuel
Planul, A. (2017) · theses.fr (ABES) · doi:10.70675/c9b178a1z8ba4z4451za409z4e80a603376f · Cited by 1
Development of safe and efficient aav vectors for retinal gene therapy
Khabou, H. (2018) · theses.fr (ABES) · doi:10.70675/aa896663z9772z4d87z9bd1z247af1f0e3f1
“AAV vectors that are capable of efficient retinal transduction from the vitreous have been designed only recently, using rational design (Boyd et al., 2015; Boye et al., 2016; Kay et al., 2013; Petrs-Silva et al., 2011) or in vivo directed evolution (Cronin et al., 2014; Dalkara et al., 2013).”
MethodVarin, J. (2020) · theses.fr (ABES) · doi:10.70675/f838cd61z108az4e28z9344z0b8ab2eae6bf · Cited by 2
Wögenstein, G. M., Ravotto, L., Todorova, V., Meister, R., Samardzija, M., Barros, L. F., Weber, B., & Grimm, C. (2026) · Science Advances · doi:10.1126/sciadv.aeg8687 · Cited by 3
“The construct containing GCaMP6s was packaged into the AAV8(double Y-F + TV)/2 capsid ( 26 , 93 ).”
Cai, Z., Liu, Y., Zhao, L., Li, X., Zhang, B., Tang, Y., Zhou, T., Zheng, Z., Li, A., Wei, J., et al. (2026) · The Open Biotechnology Journal · doi:10.2174/0118740707483472261006060307 · Cited by 1
Metadata
- Authors
- Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., Agbandje-McKenna, M., Hauswirth, W. W., Boye, S. L., & Boye, S. E.
- Affiliations
- University of Florida Health (US)
- Corresponding author
- Boye, Shannon E.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-26
- Volume
- 8
- Issue
- 4
- Pages
- e62097
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3637363
- OpenAlex
- W2067733824
- Cited by
- 168
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 1 · 2023: 7 · 2022: 11 · 2021: 14 · 2020: 17 · 2019: 16 · 2018: 19 · 2017: 14 · 2016: 21 · 2015: 24 · 2014: 11 · 2013: 5
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Update notices
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Foundation Fighting Blindness
- Research to Prevent Blindness
- National Eye Institute (P30EY021721, R01EY017549, R24EY022012)
- National Institute of General Medical Sciences (R01GM082946)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, capsid mutations, phototransduction, intravitreal delivery, retinal gene therapy, AAV2, AAV5, AAV8, off-target expression, cone photoreceptors, rod photoreceptors
- MeSH terms
- Dependovirus, Animals, Capsid, Cell Line, Chickens, Genetic Vectors, Humans, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Promoter Regions, Genetic, Serotyping, Transduction, Genetic, Gene Expression, Gene Transfer Techniques, Transgenes, Photoreceptor Cells, Vertebrate, MicroRNAs, Mice, G-Protein-Coupled Receptor Kinase 1, Viral Tropism, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.